Clinical trial
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With…
NCT00458913 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00458913 |
|---|---|
| Title | Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma |
| Official title | Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Mesothelioma |
| Intervention type | Drug |
| Interventions | bortezomib, cisplatin |
| Enrollment | 82 |
| Start date | Feb 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Mar 1, 2012 |
| First posted | Apr 11, 2007 |
| Last update posted | Jul 12, 2018 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: